Butrans and Parkinson's disease - a phase IV clinical study of FDA data

Summary:

Parkinson's disease is reported as a side effect among people who take Butrans (buprenorphine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Ms Contin, and have Adjustment disorder with depressed mood.

The phase IV clinical study analyzes which people have Parkinson's disease when taking Butrans. It is created by eHealthMe based on reports of 63,939 people who have side effects when taking Butrans from the FDA, and is updated regularly.

What is Butrans?

Butrans has active ingredients of buprenorphine. It is often used in pain. eHealthMe is studying from 64,148 Butrans users. Check the latest studies of Butrans.

What is Parkinson's disease?

Parkinson's disease is found to be associated with 1,112 drugs and 1,629 conditions by eHealthMe. Check the latest studies of Parkinson's disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 30, 2026

63,939 people reported to have side effects when taking Butrans.
Among them, 18 people (0.03%) have Parkinson's disease.

Could Butrans cause Parkinson's disease?

Among these 18 people:

How long have people been on Butrans when they have Parkinson's disease? *

What is the gender of people who have Parkinson's disease when taking Butrans? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Parkinson's disease when taking Butrans? *

What are other drugs people take besides Butrans? *

Oxycontin: 5 people, 27.78%
Ms Contin: 5 people, 27.78%
Oxycodone: 4 people, 22.22%
Zopiclone: 3 people, 16.67%
Oxycodone Hydrochloride: 3 people, 16.67%
Ryzolt: 3 people, 16.67%
Dilaudid: 3 people, 16.67%
Gliclazide: 3 people, 16.67%
Hydrocodone Bitartrate And Acetaminophen: 3 people, 16.67%
Morphine Sulfate: 3 people, 16.67%

What are other side effects people have besides Parkinson's disease? *

Drug Dependence: 5 people, 27.78%
Insomnia (sleeplessness): 4 people, 22.22%
Learning Disability (difficulty in learning): 3 people, 16.67%
Developmental Delay: 3 people, 16.67%
Cardiac Disorder: 3 people, 16.67%
Confusional State: 3 people, 16.67%
Nausea And Vomiting: 2 people, 11.11%
Lung Disorder (lung disease): 2 people, 11.11%
Diarrhea: 2 people, 11.11%
Miosis (constriction of the pupil of the eye, resulting from a normal response to an increase in light): 2 people, 11.11%

What are the existing conditions these people have? *

Adjustment Disorder With Depressed Mood: 3 people, 16.67%
Back Pain: 2 people, 11.11%
Back Injury: 2 people, 11.11%
Aggression: 2 people, 11.11%
Post-Traumatic Stress Disorder: 1 person, 5.56%
Osteoporosis (bones weak and more likely to break): 1 person, 5.56%
Neuralgia (pain in one or more nerves): 1 person, 5.56%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Butrans and have Parkinson's disease?

- Check whether Parkinson's disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Butrans:

Butrans (64,148 reports)

Browse all side effects of Butrans:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Parkinson's disease:

Parkinson's disease (1,112 drugs)

Browse all the conditions that are associated with Parkinson's disease:

Parkinson's disease (1,629 conditions)

Related publications that referenced our studies

Woulfe JM, Gray MT, Gray DA, Munoz DG, Middeldorp JM, "Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease", Parkinsonism & related disorders, 2014 Jul .
Woulfe JM, Gray MT, Gray DA, Munoz DG, Middeldorp JM, "Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease", Parkinsonism & related disorders, 2014 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on buprenorphine (the active ingredients of Butrans) and Butrans (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.